About 100 reports

  • GLOBAL SCLERODERMA TREATMENT MARKET BY OTHERS DRUG CLASS 2016-2021 ($ MILLIONS)
  • COMPETITIVE SCENARIO

Long-term use of analgesics causes gastrointestinal problems.

  • Dermatological Condition
  • AstraZeneca PLC
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • MERCK & COMPANY
  • PRODUCT DESCRIPTION

SYSTEMIC TETRACYCLINE MAY CAUSE GASTROINTESTINAL UPSET, NAUSEA, DIARRHEA, AND VAGINAL YEAST INFECTION.

  • Dermatological Condition
  • Managed Care
  • World
  • Market Size
  • Galderma S.A.

Students are also demonstrated the examination of gastrointestinal endoscopy.

  • Healthcare
  • Managed Care
  • Medical Education
  • World
  • Market Size
  • 2.3.3 Psoriasis
  • Appendix

Minor AEs such as stomatitis, headaches, fatigue and gastrointestinal problems such as nausea and vomiting may occur when using Metolate.

  • Dermatological Condition
  • World
  • AbbVie Inc.
  • Allergan plc
  • Amgen Inc.

It acquired Salix Pharmaceuticals in 2015 to enter the gastrointestinal segment and divested some of the key brands such as AMBI.

  • Dermatological Condition
  • Forecast
  • Almirall, S.A.
  • Galderma S.A.
  • Valeant Pharmaceuticals International, Inc.
  • Vendor landscape

It also focuses on developing and introducing new treatments in the areas of dermatology, neurology, and gastrointestinal disorders.

  • Dermatological Condition
  • World
  • Bayer AG
  • Mylan Inc.
  • Valeant Pharmaceuticals International, Inc.
  • Dermatology Therapeutics Market, Global, Pipeline Programs Targeting ORAI1, 2017
  • 4.4.3 Psoriasis

It is also in development for various indications in the gastrointestinal, respiratory, and ophthalmology therapy areas.

  • Dermatological Condition
  • World
  • Market Size
  • Allergan plc
  • Apricus Biosciences, Inc.

ORAL MEDICATIONS THAT INCLUDE ANTIBIOTICS AND RETINOIDS HAVE LED TO INCREASED HEPATOTOXICITY, GASTROINTESTINAL ISSUES AND SUICIDAL TENDENCIES, ALONG WITH THE ABOVE MENTIONED ISSUES.

  • Dermatological Condition
  • World
  • Forecast
  • Allergan plc
  • Valeant Pharmaceuticals International, Inc.
  • VI. RISK FACTORS
  • a. Approved Products

RISK FACTORS severe acne was related to a higher prevalence of one or more gastrointestinal, sinopulmonary, and psychological co-morbid disorders.

  • Dermatological Condition
  • Allergan plc
  • Foamix Ltd.
  • GlaxoSmithKline plc
  • Novartis AG
  • a. Approved Products
  • VI. RISK FACTORS

RISK FACTORS severe acne was related to a higher prevalence of one or more gastrointestinal, sinopulmonary, and psychological co-morbid disorders.

  • Dermatological Condition
  • Allergan plc
  • Foamix Ltd.
  • GlaxoSmithKline plc
  • Novartis AG
  • 2.4 Co-morbidities and Complications
  • Pipeline Landscape Assessment

Minor AEs such as stomatitis, headaches, fatigue and gastrointestinal problems such as nausea and vomiting may occur when using methotrexate.

  • Dermatological Condition
  • World
  • Market Size
  • Amgen Inc.
  • Biologics, Inc.

We are one of the nation' s Top ## health systems.

  • Managed Care
  • United States
  • Company
  • Supply
  • GlobalData's company
  • DESCRIPTION OF DISORDERS

Systemic tetracycline may cause gastrointestinal upset, nausea, diarrhea, and vaginal yeast infection.

  • Dermatological Condition
  • Managed Care
  • Allergan plc
  • Galderma S.A.
  • Pfizer Inc.

You can easily book an appointment with one online.

  • Acne Treatment
  • Dermatological Condition
  • Pharmaceutical
  • Allergan plc
  • Galderma S.A.
  • FDA
  • Global Acne Grading System

A study reported that severe acne was related to a higher prevalence of one or more gastrointestinal, sinopulmonary, and psychological co-morbid disorders.

  • Dermatological Condition
  • India
  • Allergan plc
  • Cipla Ltd
  • Novartis AG

Asian Nursing Research; ##(##): ##-##.

  • Dermatological Condition
  • Managed Care
  • Actimmune group
  • Anacor Pharmaceuticals, Inc.
  • Astellas Pharma Inc.

The company' s digestive health products include diagnostics and therapeutics, gastrointestinal endoscopy products, enteral feeding tubes and accessories.

  • Respiratory Monitoring
  • Eastern Europe
  • Russia
  • Forecast
  • CareFusion Corporation
  • 7 Pipeline Assessment

Asian Nursing Research; ##(##): ##-##.

  • Dermatological Condition
  • Managed Care
  • Actimmune group
  • Anacor Pharmaceuticals, Inc.
  • Novartis AG
  • 7 Pipeline Assessment

Asian Nursing Research; ##(##): ##-##.

  • Dermatological Condition
  • Managed Care
  • Actimmune group
  • Anacor Pharmaceuticals, Inc.
  • Novartis AG
  • 7 Pipeline Assessment

Asian Nursing Research; ##(##): ##-##.

  • Dermatological Condition
  • Managed Care
  • Actimmune group
  • Anacor Pharmaceuticals, Inc.
  • Novartis AG

GASTROINTESTINAL COMPLICATIONS ARE COMMON AND INCLUDE IMPAIRED MOTILITY, DIGESTION, ABSORPTION, AND EXCRETION DUE TO THE ATROPHY OF THE GASTROINTESTINAL (GI) TRACT.

  • Autoimmune Disease
  • Dermatological Condition
  • Managed Care
  • GlobalData's company
  • Roche Group

PLOS ONE; ##(##): E##.

  • Dermatological Condition
  • Managed Care
  • World
  • Allergan plc
  • Cellceutix Corporation

PLOS ONE; ##(##): E##.

  • Dermatological Condition
  • Managed Care
  • Cempra, Inc.
  • Debiopharm Group
  • Melinta Therapeutics, Inc.

PLOS ONE; ##(##): E##.

  • Dermatological Condition
  • Managed Care
  • Cempra, Inc.
  • Debiopharm Group
  • Melinta Therapeutics, Inc.

PLOS ONE; ##(##): E##.

  • Dermatological Condition
  • Managed Care
  • Cempra, Inc.
  • Debiopharm Group
  • Melinta Therapeutics, Inc.
  • Dormant Products, H1 2018 (Contd..1), H1 2018

Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Pipeline Review, H1 2018 Summary Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis...

  • Dermatological Condition
  • Therapy
  • United States
  • World
  • Product Initiative
  • DORMANT PRODUCTS, H2 2017 (CONTD..1), H2 2017
  • GLOBAL MARKETS DIRECT REPORT COVERAGE

It targets tumor necrosis factor receptor ## (TNFR-##).

  • Dermatological Condition
  • Therapy
  • United States
  • World
  • Product Initiative
  • Proportion of Systemic Mastocytosis to Gastrointestinal Clinical Trials, G7 Countries (%), 2015*
  • Clinical Trials by E7 Countries: Proportion of Systemic Mastocytosis to Gastrointestinal Clinical Trials

Systemic Mastocytosis Global Clinical Trials Review, H2, 2015 Summary GlobalData's clinical trial report, “Systemic Mastocytosis Global Clinical Trials Review, H2, 2015" provides an overview of Systemic Mastocytosis clinical trials scenario. This report provides top line data relating to the clinical trials on Systemic...

  • Dermatological Condition
  • Pathology
  • Therapy
  • World
  • Product Initiative
  • PIPELINE BY AB SCIENCE SA, H1 2017
  • Amyotrophic Lateral Sclerosis

ALS patients received riluzole plus masitinib ##. ## mg/ kg/ day, ##. ## mg/ kg/ day, or placebo (##:##:##) up to ## weeks.

  • Dermatological Condition
  • Europe
  • European Union
  • Product Initiative
  • AB Science SA
  • EQUITY OFFERING
  • ASSET TRANSACTIONS

Southlake TX ## United States Tel: +## ## ## Fax: +## ## ## Url: www. thermi. com Poli Group Holding Srl Switzerland Almirall Sofotec GmbH Benzstrasse ##-##, < br> Bad Homburg v. d.

  • Dermatological Condition
  • Digestive System Disorder
  • Managed Care
  • Company Financials
  • Almirall, S.A.